Shaping the Future of Human Health
Innovation is the lifeblood of medical advancement.
This is what we believe. This is what drives us.
What We Do
We advance human health worldwide by incubating companies, educating stakeholders, and bringing innovators, industry, and government together to strengthen the startup medtech ecosystem.
Why We Do It
We are committed to making a meaningful difference in the lives of patients and their families around the globe. We are here to give back to others while creating something of lasting value.
Who We Are
We are a team of seasoned industry professionals who have dedicated our careers to the invention, development, and deployment of new health technologies into clinical care.
Fogarty Innovation is a nonprofit organization dedicated to advancing medical innovation that improves human health. We do this in three primary ways:
Create Companies: As an incubator and accelerator, our experienced staff provides immersive support to help early-stage companies hone their strategies, build their teams, and navigate the path to commercialization. Earlier in the pipeline, we help aspiring innovators evaluate promising ideas and answer the difficult questions that determine how, or whether, to take a concept forward. We help innovators get their ideas to patients.
Educate Stakeholders: Because transforming ideas into great technologies, services, and companies is a complex process, we provide practical educational programming that addresses challenges across the innovation lifecycle. Taught by real-world experts, our courses clarify the medtech landscape, illuminate current best practices, encourage lively discussion, and foster lasting personal connections. Programs are tailored for specific audiences, which include students, entrepreneurs, industry peers, and government representatives. We believe innovation is a discipline that can be taught and honed.
Elevate the Ecosystem: We leverage our unique status as a nonprofit to bring together disparate public and private entities and forge alliances that help innovation thrive. By increasing understanding and cooperation among innovators, industry, academia, and government, we can address social issues and influence policy decisions that strengthen the early-stage medtech ecosystem. We are stronger together.
What’s Happening at Fogarty Innovation
The cultivation of medical technology companies at various stages of development is at the heart of Fogarty Innovation’s mission, and the core of our history. From day one, we have teamed with medtech pioneers through our tailored incubation and acceleration programs. Get to know some of our current entrepreneurs and the groundbreaking ideas we are helping them translate into game-changing solutions for patients worldwide.
Diabetic retinopathy is among the leading causes of vision loss in the world, affecting more than 230 million people, especially medically underserved populations. While there is no cure, there are a variety of treatments that must be applied as early as possible to prevent further damage. Bioxytech Retina is developing the first device that can detect DR using functional imaging, before a patient suffers vision loss.
Autoimmune diseases are the third most common category of disease in the United States, affecting up to 27 million people. Boomerang Medical is a bioelectronic medicine company developing technology to advance the treatment of autoimmune diseases by harnessing the body’s own “peripheral wiring” in order to manage inflammation and immune response. Boomerang Medical is backed by Arboretum Ventures, a venture capital firm specializing in companies that improve patient outcomes and reduce healthcare system costs.
While many of our vital signs are easily obtained, the one test that doctors rely on to make the majority of their diagnoses—the blood test—can take hours, if not days, for results. Chronus Health has developed a portable device that provides lab results in minutes, allowing for real-time diagnosis and promising to dramatically improve time-to-care and patient outcomes. The startup has focused its initial efforts on complete blood count (CBC) and comprehensive metabolic panel (CMP), which account for 50 percent of all blood tests performed in the United States.
Otitis Media with Effusion (OME) is one of the most frequent infectious diseases in children and is the most common cause of acquired hearing loss in childhood. The disease commonly affects children between the ages of 1 and 6. EarFlo is a precision, non-invasive medical device disguised as a sippy cup that treats OME during natural drinking, allowing caregivers to treat the condition at home and avoid surgery.
Current chronic therapies for short bowel syndrome (SBS), a malabsorption disorder caused by the lack of a functional small intestine, include expensive medication and intestinal surgery. These approaches have low success rates and a staggering average 5-year cost of care of $1.6 million per patient. Eclipse Regenesis is developing the first restorative therapy for pediatric and adult SBS patients with the Eclipse XL1 Distraction Enterogenesis System, which harnesses the body’s own tissue regenerative capabilities to produce new, fully functional intestine.
Skin cancer is the most common form of malignancy, with more individuals diagnosed each year than for all other cancers combined. For the last 150 years, these malignancies have required an invasive biopsy for diagnosis, but Enspectra is leading a digital transformation in pathology by imaging real-time cellular anatomy in living tissue, without cuts or stains.
More than 110 million people worldwide suffer from non-healing, open wounds. High costs and overly complex technology severely limit, or even preclude, access to advanced wound care technology. Healyx Labs is developing the lowest-cost and easiest-to-use wound vacuum technology for price-sensitive and underserved markets.
One hundred seventy-eight million adults in the United States are missing at least one tooth, and a surprising 40 million are missing all their teeth. Dental implants are the top treatment choice of treatment, but this solution is utilized by less than 2 percent of those impacted by tooth loss because of limited accessibility, high cost, high risk and long treatment time. iDentical is leveraging the latest 3D technology to offer a safer, faster and more affordable solution through its drill-free, non-invasive dental implants.
Immergo Labs is a virtual reality telehealth platform that connects therapists and patients for physical rehabilitation services. Immergo uses artificial intelligence and virtual reality (VR) to incorporate telehealth capabilities and enhance the accessibility, experience, and accuracy of remote physical therapy care. With just a VR headset, the platform connects patients and therapists as if they were interacting live.
Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed an obstetrics and gynecology platform of medical devices: the first, Prep, is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time; the second, Milli, is helping treat pelvic pain and dyspareunia.
As the third-leading cause of death worldwide, chronic obstructive pulmonary disease (COPD) is a group of diseases that causes airway blockage and breathing problems. Ryme is focused on alleviating the suffering of patients who struggle to breathe by targeting the autonomous nervous system. The condition impacts more than 375 million people worldwide at an annual cost of approximately $50 billion and is a huge burden to healthcare systems around the world.
Who We Work With
The medical technology ecosystem is shaped by a variety of interconnected constituents—private and public, financial and philanthropic, academic and industrial. Our nonprofit status and years of experience working with these stakeholders give us a unique ability to bring these disparate groups together and build collaborations that advance innovative solutions towards patient care.
– Venture Capitalist
The growing list of groups with whom we are proud to actively collaborate includes:
Medtech Advocacy Groups
Other Global Innovation Programs
The Investment Community
Developing healthcare solutions for a diverse population requires innovation teams fueled by disparate viewpoints, backgrounds, opinions, and experiences. To improve diversity in the health technology innovation ecosystem, we teamed up with Stanford Biodesign to found and support Diversity by Doing Healthtech. Learn more about DxD as well as our partnerships with other organizations dedicated to diversity.
Join Our Journey
We are all innovators and have something novel to bring to life—whether that is a creative idea, a new technology, or simply the conviction that there must be a better way. If healthcare is your passion—and you’re driven to shape its future—we encourage you to learn more about Fogarty Innovation’s audacious vision. Help us turn possibilities into realities. Contact us to begin your journey.
Latest Blogs and Videos
Nina Capital Shares Insights on Early-Stage Financing and Trends from Across the Pond
After 13 years working with entrepreneurs, investors, universities and corporations in Silicon Valley, Marta-Gaia Zanchi, the founding director of Stanford Biodesign’s digital...
Diverse Community College Students Explore “Pathways in Health Technology” With Innovative Program
Stanford Biodesign, Fogarty Innovation and five local medical device companies have teamed up to introduce a new program offered through the Diversity by Doing (DxD)...
Fogarty Innovation Graduate Raydiant Oximetry Kicks Off Series B Financing Round with an Investment from March of Dimes
Fogarty graduate Raydiant Oximetry, Inc., kicked off its Series B financing round with an investment from the March of Dimes Innovation Fund. The cash infusion comes on the heels...